プロテアーゼ活性化受容体2 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "プロテアーゼ活性化受容体2" in Japanese language version.

refsWebsite

Global rank Japanese rank

46nih.gov

4^th place

24^th place

26doi.org

2^nd place

6^th place

2ensembl.org

1,626^th place

2,625^th place

2wikipedia.org

low place

2harvard.edu

18^th place

107^th place

1worldcat.org

5^th place

19^th place

1uq.edu.au

3,558^th place

7,223^rd place

doi.org

Heuberger, Dorothea M.; Schuepbach, Reto A. (2019). “Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases”. Thrombosis Journal 17: 4. doi:10.1186/s12959-019-0194-8. ISSN 1477-9560. PMC 6440139. PMID 30976204.
“Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism”. FASEB Journal 27 (12): 4757–67. (December 2013). doi:10.1096/fj.13-232702. PMID 23964081.
“Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation”. Nature Medicine 17 (11): 1490–7. (October 2011). doi:10.1038/nm.2461. PMC 3210891. PMID 22019885.
“Protease-Activated Receptors in the Intestine: Focus on Inflammation and Cancer” (英語). Frontiers in Endocrinology 10: 717. (2019). doi:10.3389/fendo.2019.00717. PMC 6821688. PMID 31708870.
“PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR”. British Journal of Pharmacology 178 (4): 913–932. (November 2020). doi:10.1111/bph.15332. PMID 33226635.
“Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis”. Yonsei Medical Journal 51 (6): 808–22. (November 2010). doi:10.3349/ymj.2010.51.6.808. PMC 2995962. PMID 20879045.
“Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease”. Drug News & Perspectives 21 (7): 369–81. (September 2008). doi:10.1358/dnp.2008.21.7.1255294. PMID 19259550.
“Protease-activated receptors and their biological role - focused on skin inflammation”. The Journal of Pharmacy and Pharmacology 67 (12): 1623–33. (December 2015). doi:10.1111/jphp.12447. PMID 26709036.
“Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo”. The Journal of Pharmacology and Experimental Therapeutics 309 (3): 1098–107. (June 2004). doi:10.1124/jpet.103.061010. PMID 14976227.
“Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2: Another Target for Thrombin Signaling”. Molecular Pharmacology 89 (5): 606–14. (May 2016). doi:10.1124/mol.115.102723. PMID 26957205.
“Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2”. American Journal of Physiology. Lung Cellular and Molecular Physiology 278 (1): L193-201. (January 2000). doi:10.1152/ajplung.2000.278.1.l193. PMID 10645907.
“Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development”. Journal of Medicinal Chemistry 55 (15): 6669–86. (August 2012). doi:10.1021/jm300407t. PMID 22607152.
“Macrophage TLR4 and PAR2 Signaling: Role in Regulating Vascular Inflammatory Injury and Repair” (英語). Frontiers in Immunology 11: 2091. (2020). doi:10.3389/fimmu.2020.02091. PMC 7530636. PMID 33072072.
“PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR”. British Journal of Pharmacology 178 (4): 913–932. (November 2020). doi:10.1111/bph.15332. PMID 33226635.
“Protease-activated receptors and their biological role - focused on skin inflammation”. The Journal of Pharmacy and Pharmacology 67 (12): 1623–33. (December 2015). doi:10.1111/jphp.12447. PMID 26709036.
“Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2”. American Journal of Physiology. Lung Cellular and Molecular Physiology 278 (1): L193-201. (January 2000). doi:10.1152/ajplung.2000.278.1.l193. PMID 10645907.
“Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells”. Journal of Immunology 168 (7): 3577–85. (April 2002). doi:10.4049/jimmunol.168.7.3577. PMID 11907122.
“Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice”. PLOS ONE 8 (2): e55965. (2013-02-07). Bibcode: 2013PLoSO...855965H. doi:10.1371/journal.pone.0055965. PMC 3567012. PMID 23409098.
“Protease-activated receptors (PARs) in cancer: Novel biased signaling and targets for therapy”. Methods in Cell Biology 132: 341–58. (2016). doi:10.1016/bs.mcb.2015.11.006. PMID 26928551.
“Identification and characterization of novel small-molecule protease-activated receptor 2 agonists”. The Journal of Pharmacology and Experimental Therapeutics 327 (3): 799–808. (December 2008). doi:10.1124/jpet.108.142570. PMID 18768780.
“Novel agonists and antagonists for human protease activated receptor 2”. Journal of Medicinal Chemistry 53 (20): 7428–40. (October 2010). doi:10.1021/jm100984y. PMID 20873792.
“PAR2 Modulators Derived from GB88”. ACS Medicinal Chemistry Letters 7 (12): 1179–1184. (December 2016). doi:10.1021/acsmedchemlett.6b00306. PMC 5150695. PMID 27994760.
“Biased signaling of protease-activated receptors”. Frontiers in Endocrinology 5: 67. (2014). doi:10.3389/fendo.2014.00067. PMC 4026716. PMID 24860547.
“Biased Signaling by Agonists of Protease Activated Receptor 2”. ACS Chemical Biology 12 (5): 1217–1226. (May 2017). doi:10.1021/acschembio.6b01088. PMID 28169521.
“Structural insight into allosteric modulation of protease-activated receptor 2”. Nature 545 (7652): 112–115. (May 2017). Bibcode: 2017Natur.545..112C. doi:10.1038/nature22309. PMID 28445455.
“Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling”. ACS Pharmacology & Translational Science 1 (2): 119–133. (November 2018). doi:10.1021/acsptsci.8b00019. PMC 7088944. PMID 32219208.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000164251 - Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000021678 - Ensembl, May 2017

harvard.edu

ui.adsabs.harvard.edu

“Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice”. PLOS ONE 8 (2): e55965. (2013-02-07). Bibcode: 2013PLoSO...855965H. doi:10.1371/journal.pone.0055965. PMC 3567012. PMID 23409098.
“Structural insight into allosteric modulation of protease-activated receptor 2”. Nature 545 (7652): 112–115. (May 2017). Bibcode: 2017Natur.545..112C. doi:10.1038/nature22309. PMID 28445455.

nih.gov

pubmed.ncbi.nlm.nih.gov

Heuberger, Dorothea M.; Schuepbach, Reto A. (2019). “Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases”. Thrombosis Journal 17: 4. doi:10.1186/s12959-019-0194-8. ISSN 1477-9560. PMC 6440139. PMID 30976204.
“Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism”. FASEB Journal 27 (12): 4757–67. (December 2013). doi:10.1096/fj.13-232702. PMID 23964081.
“Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation”. Nature Medicine 17 (11): 1490–7. (October 2011). doi:10.1038/nm.2461. PMC 3210891. PMID 22019885.
“Protease-Activated Receptors in the Intestine: Focus on Inflammation and Cancer” (英語). Frontiers in Endocrinology 10: 717. (2019). doi:10.3389/fendo.2019.00717. PMC 6821688. PMID 31708870.
“PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR”. British Journal of Pharmacology 178 (4): 913–932. (November 2020). doi:10.1111/bph.15332. PMID 33226635.
“Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis”. Yonsei Medical Journal 51 (6): 808–22. (November 2010). doi:10.3349/ymj.2010.51.6.808. PMC 2995962. PMID 20879045.
“Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease”. Drug News & Perspectives 21 (7): 369–81. (September 2008). doi:10.1358/dnp.2008.21.7.1255294. PMID 19259550.
“Protease-activated receptors and their biological role - focused on skin inflammation”. The Journal of Pharmacy and Pharmacology 67 (12): 1623–33. (December 2015). doi:10.1111/jphp.12447. PMID 26709036.
“Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo”. The Journal of Pharmacology and Experimental Therapeutics 309 (3): 1098–107. (June 2004). doi:10.1124/jpet.103.061010. PMID 14976227.
“Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2: Another Target for Thrombin Signaling”. Molecular Pharmacology 89 (5): 606–14. (May 2016). doi:10.1124/mol.115.102723. PMID 26957205.
“Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2”. American Journal of Physiology. Lung Cellular and Molecular Physiology 278 (1): L193-201. (January 2000). doi:10.1152/ajplung.2000.278.1.l193. PMID 10645907.
“Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development”. Journal of Medicinal Chemistry 55 (15): 6669–86. (August 2012). doi:10.1021/jm300407t. PMID 22607152.
“Macrophage TLR4 and PAR2 Signaling: Role in Regulating Vascular Inflammatory Injury and Repair” (英語). Frontiers in Immunology 11: 2091. (2020). doi:10.3389/fimmu.2020.02091. PMC 7530636. PMID 33072072.
“PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR”. British Journal of Pharmacology 178 (4): 913–932. (November 2020). doi:10.1111/bph.15332. PMID 33226635.
“Protease-activated receptors and their biological role - focused on skin inflammation”. The Journal of Pharmacy and Pharmacology 67 (12): 1623–33. (December 2015). doi:10.1111/jphp.12447. PMID 26709036.
“Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2”. American Journal of Physiology. Lung Cellular and Molecular Physiology 278 (1): L193-201. (January 2000). doi:10.1152/ajplung.2000.278.1.l193. PMID 10645907.
“Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells”. Journal of Immunology 168 (7): 3577–85. (April 2002). doi:10.4049/jimmunol.168.7.3577. PMID 11907122.
“Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice”. PLOS ONE 8 (2): e55965. (2013-02-07). Bibcode: 2013PLoSO...855965H. doi:10.1371/journal.pone.0055965. PMC 3567012. PMID 23409098.
“Protease-activated receptors (PARs) in cancer: Novel biased signaling and targets for therapy”. Methods in Cell Biology 132: 341–58. (2016). doi:10.1016/bs.mcb.2015.11.006. PMID 26928551.
“Identification and characterization of novel small-molecule protease-activated receptor 2 agonists”. The Journal of Pharmacology and Experimental Therapeutics 327 (3): 799–808. (December 2008). doi:10.1124/jpet.108.142570. PMID 18768780.
“Novel agonists and antagonists for human protease activated receptor 2”. Journal of Medicinal Chemistry 53 (20): 7428–40. (October 2010). doi:10.1021/jm100984y. PMID 20873792.
“PAR2 Modulators Derived from GB88”. ACS Medicinal Chemistry Letters 7 (12): 1179–1184. (December 2016). doi:10.1021/acsmedchemlett.6b00306. PMC 5150695. PMID 27994760.
“Biased signaling of protease-activated receptors”. Frontiers in Endocrinology 5: 67. (2014). doi:10.3389/fendo.2014.00067. PMC 4026716. PMID 24860547.
“Biased Signaling by Agonists of Protease Activated Receptor 2”. ACS Chemical Biology 12 (5): 1217–1226. (May 2017). doi:10.1021/acschembio.6b01088. PMID 28169521.
“Structural insight into allosteric modulation of protease-activated receptor 2”. Nature 545 (7652): 112–115. (May 2017). Bibcode: 2017Natur.545..112C. doi:10.1038/nature22309. PMID 28445455.
“Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling”. ACS Pharmacology & Translational Science 1 (2): 119–133. (November 2018). doi:10.1021/acsptsci.8b00019. PMC 7088944. PMID 32219208.

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

uq.edu.au

espace.library.uq.edu.au

“Biased Signaling by Agonists of Protease Activated Receptor 2”. ACS Chemical Biology 12 (5): 1217–1226. (May 2017). doi:10.1021/acschembio.6b01088. PMID 28169521.

wikipedia.org

en.wikipedia.org

GRCh38: Ensembl release 89: ENSG00000164251 - Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000021678 - Ensembl, May 2017

worldcat.org

search.worldcat.org

Heuberger, Dorothea M.; Schuepbach, Reto A. (2019). “Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases”. Thrombosis Journal 17: 4. doi:10.1186/s12959-019-0194-8. ISSN 1477-9560. PMC 6440139. PMID 30976204.